| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
|
Nature
|
2008
|
5.98
|
|
2
|
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
|
Proc Natl Acad Sci U S A
|
2010
|
5.60
|
|
3
|
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
|
Proc Natl Acad Sci U S A
|
2011
|
3.99
|
|
4
|
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
|
Clin Cancer Res
|
2013
|
3.25
|
|
5
|
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
|
J Clin Oncol
|
2011
|
2.33
|
|
6
|
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.
|
Cancer
|
2010
|
2.13
|
|
7
|
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
|
Cancer Res
|
2009
|
2.04
|
|
8
|
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.
|
J Mol Diagn
|
2012
|
1.99
|
|
9
|
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
|
Proc Natl Acad Sci U S A
|
2002
|
1.89
|
|
10
|
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
|
Hum Pathol
|
2007
|
1.49
|
|
11
|
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
|
Am J Obstet Gynecol
|
2012
|
1.43
|
|
12
|
An evaluation of cervical cancer in women age sixty and over.
|
Gynecol Oncol
|
2008
|
1.43
|
|
13
|
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.
|
Cancer Res
|
2013
|
1.43
|
|
14
|
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
|
Mol Cancer Res
|
2007
|
1.40
|
|
15
|
Hereditary ovarian cancer: beyond the usual suspects.
|
Gynecol Oncol
|
2012
|
1.24
|
|
16
|
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
|
Gynecol Oncol
|
2008
|
1.15
|
|
17
|
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
|
Cancer
|
2012
|
1.14
|
|
18
|
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
|
Am J Obstet Gynecol
|
2006
|
1.12
|
|
19
|
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
|
Proc Natl Acad Sci U S A
|
2013
|
1.11
|
|
20
|
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.
|
Nucleic Acids Res
|
2011
|
1.08
|
|
21
|
Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
|
Gynecol Oncol
|
2012
|
1.06
|
|
22
|
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.
|
Genes Chromosomes Cancer
|
2010
|
1.05
|
|
23
|
Secondary mutations of BRCA1/2 and drug resistance.
|
Cancer Sci
|
2011
|
1.05
|
|
24
|
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.
|
Cancer Res
|
2007
|
1.01
|
|
25
|
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
|
Cancer Res
|
2010
|
1.01
|
|
26
|
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.
|
Cancer Lett
|
2010
|
1.01
|
|
27
|
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
|
J Clin Invest
|
2016
|
0.94
|
|
28
|
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.
|
Gynecol Oncol
|
2008
|
0.93
|
|
29
|
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
|
Genes Chromosomes Cancer
|
2007
|
0.92
|
|
30
|
A self-administered family history questionnaire improves identification of women who warrant referral to genetic counseling for hereditary cancer risk.
|
Gynecol Oncol
|
2012
|
0.89
|
|
31
|
Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy.
|
J Genet Couns
|
2002
|
0.88
|
|
32
|
PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
|
Int J Gynecol Pathol
|
2012
|
0.87
|
|
33
|
Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review.
|
Appl Immunohistochem Mol Morphol
|
2008
|
0.87
|
|
34
|
Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time.
|
J Natl Cancer Inst
|
2012
|
0.85
|
|
35
|
53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
|
Gynecol Oncol
|
2012
|
0.83
|
|
36
|
Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.
|
Gynecol Oncol
|
2005
|
0.83
|
|
37
|
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
|
Gynecol Oncol
|
2012
|
0.81
|
|
38
|
Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
|
Int J Gynecol Cancer
|
2012
|
0.81
|
|
39
|
E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
|
Genes Chromosomes Cancer
|
2012
|
0.79
|
|
40
|
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
|
Neoplasia
|
2010
|
0.79
|
|
41
|
Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.
|
Int J Gynecol Pathol
|
2015
|
0.76
|
|
42
|
Duration of cisplatin excretion in breast milk.
|
J Hum Lact
|
2013
|
0.76
|
|
43
|
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
|
Cancer Genet Cytogenet
|
2008
|
0.75
|
|
44
|
Defining women at high risk of ovarian cancer.
|
Cancer Res
|
2007
|
0.75
|
|
45
|
Granulin: biomarker or interesting window into host/tumor biology?
|
Gynecol Oncol
|
2011
|
0.75
|
|
46
|
Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma.
|
Transl Oncol
|
2012
|
0.75
|
|
47
|
Spontaneous Twin Pregnancy After Oophoropexy and Pelvic Radiation for Rectal Cancer.
|
Obstet Gynecol
|
2016
|
0.75
|
|
48
|
Gynecologic cancer genomics in the modern era.
|
Gynecol Oncol
|
2013
|
0.75
|
|
49
|
Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary?
|
Int J Gynecol Pathol
|
2008
|
0.75
|